Tempanginol® (Tablets) Instructions for Use
Marketing Authorization Holder
Balkanpharma-Dupnitsa, AD (Bulgaria)
ATC Code
N02BB72 (Metamizole sodium in combination with psycholeptics)
Dosage Form
| Tempanginol® | Film-coated tablets: 10, 20, 300, or 1000 pcs. |
Dosage Form, Packaging, and Composition
Film-coated tablets round, biconvex; on the break – a white core with a fine-grained structure, surrounded by a continuous green layer of the film coating.
| 1 tab. | |
| Metamizole sodium | 500 mg |
| Triacetonamide 4-toluenesulfonate | 20 mg |
Excipients: wheat starch, microcrystalline cellulose, povidone, talc, magnesium stearate, ethanol, purified water.
Coating composition Eudragit L, talc, titanium dioxide, macrogol 400, glycerol, castor oil, polysorbate 80, dyes (Eurocert Quinoline Yellow 70 (E104), Spectracol Patent blue V (E131)), purified water, acetone, isopropanol.
10 pcs. – blisters (1) – cardboard boxes.
Clinical-Pharmacological Group
Combination analgesic-antipyretic
Pharmacotherapeutic Group
Combined non-narcotic analgesic agent
Pharmacological Action
The instructions were approved by the Pharmacological Committee of the Ministry of Health of Russia on September 27, 2001.
Tempanginol® is a combined preparation containing the non-narcotic analgesic metamizole (analgin) and the tranquilizer triacetonamine 4-toluenesulfonate. It has analgesic, antipyretic, weak anti-inflammatory, and sedative effects.
Indications
- Moderate or mild pain syndrome, especially in patients with increased nervous excitability: headache, toothache, migraine pain, neuralgia, radicular syndrome, myalgia, dysmenorrhea;
- For mild pains of visceral origin (renal, hepatic, intestinal colic) in combination with antispasmodic agents;
- As an auxiliary agent, it can be used to reduce pain after surgical and diagnostic interventions;
- Elevated temperature in colds and other infectious and inflammatory diseases.
ICD codes
| ICD-10 code | Indication |
| G43 | Migraine |
| J06.9 | Acute upper respiratory infection, unspecified |
| K08.8 | Other specified disorders of teeth and supporting structures (including toothache) |
| K80 | Cholelithiasis [cholelithiasis] (including biliary colic) |
| M54.3 | Sciatica |
| M54.4 | Lumbago with sciatica |
| M79.1 | Myalgia |
| M79.2 | Neuralgia and neuritis, unspecified |
| N23 | Unspecified renal colic |
| N94.4 | Primary dysmenorrhea |
| N94.5 | Secondary dysmenorrhea |
| R10.4 | Other and unspecified abdominal pain (colic) |
| R50 | Fever of unknown origin |
| R51 | Headache |
| R52.0 | Acute pain |
| R52.2 | Other chronic pain |
| ICD-11 code | Indication |
| 8A80.Z | Migraine, unspecified |
| 8A8Z | Headache disorders, unspecified |
| 8E4A.1 | Paraneoplastic or autoimmune diseases of the peripheral or autonomic nervous system |
| CA07.0 | Acute upper respiratory tract infection of unspecified site |
| DA0A.Z | Diseases of teeth and supporting structures, unspecified |
| DC11.Z | Cholelithiasis, unspecified |
| DD93.1 | Infantile colic |
| FB56 | Specified soft tissue diseases, not elsewhere classified |
| FB56.2 | Myalgia |
| GA34.3 | Dysmenorrhea |
| LA30.5Z | Anomalies of tooth resorption or loss, unspecified |
| MD81.4 | Other and unspecified abdominal pain |
| ME84.20 | Lumbago with sciatica |
| ME84.3 | Sciatica |
| MF56 | Renal colic |
| MG26 | Fever of other or unknown origin |
| MG30.Z | Chronic pain syndrome, unspecified |
| MG31.Z | Acute pain, unspecified |
Dosage Regimen
| The method of application and dosage regimen for a specific drug depend on its form of release and other factors. The optimal dosage regimen is determined by the doctor. It is necessary to strictly adhere to the compliance of the dosage form of a specific drug with the indications for use and dosage regimen. |
The tablets are taken orally, without chewing, with a sufficient amount of liquid, during or after a meal. The usual dose for adults is 1 tab. 1-3 times/day. The maximum single dose is 2 tabs, the maximum daily dose is 6 tabs. The duration of administration is no more than 5 days. Increasing the daily dose of the drug or the duration of treatment is possible only under medical supervision. With long-term (more than a week) use of the drug, monitoring of the peripheral blood picture and the functional state of the liver is necessary.
Adverse Reactions
In some cases, a burning sensation in the epigastric region, dry mouth, and headache have been noted.
Allergic reactions in case of hypersensitivity to some components (skin rash, itching, Quincke’s edema), rarely – anaphylactic shock.
From the nervous system dizziness, extremely rarely hallucinations.
From the cardiovascular system decrease in blood pressure, tachycardia, cyanosis.
From the hematopoietic system agranulocytosis, leukopenia, thrombocytopenia.
From the respiratory system in case of a tendency to bronchospasm, an attack may be provoked.
From the digestive system cholestasis, jaundice, increased transaminase levels, hyperbilirubinemia.
From the genitourinary system impaired renal function (in high doses).
Due to the tranquilizing effect of triacetonamide 4-toluenesulfonate, the drug should not be used when driving vehicles and other activities requiring increased attention.
Contraindications
- Hypersensitivity to analgin (sodium metamizole), pyrazolone derivatives or triacetone-4-toluenesulfonate;
- Severe impairment of liver and kidney function;
- Heart failure;
- Arterial hypotension;
- Inhibition of hematopoiesis (agranulocytosis);
- Hereditary hemolytic anemia associated with glucose-6-phosphate dehydrogenase deficiency;
- Pregnancy;
- Breastfeeding period;
- Childhood (up to 14 years).
Use in Pregnancy and Lactation
Contraindicated during pregnancy and breastfeeding.
Use in Hepatic Impairment
Contraindicated: severe impairment of liver function.
Use in Renal Impairment
Contraindicated: severe impairment of kidney function.
Pediatric Use
Contraindicated: childhood (up to 14 years).
For adolescents under 18 years of age, use only as prescribed by a doctor.
Special Precautions
Use with caution in patients with impaired liver or kidney function, with a tendency to arterial hypotension, and in patients with allergies.
With long-term (more than a week) use of the drug, monitoring of the blood picture and the functional state of the liver is necessary.
It is not recommended to consume alcohol during the drug intake.
For adolescents under 18 years of age, use only as prescribed by a doctor.
Overdose
Nausea, vomiting, pain in the epigastric region. The victim should consult a doctor immediately.
First aid gastric lavage, administration of activated charcoal.
Drug Interactions
Concomitant use of Tempanginol® with other non-narcotic analgesics may lead to mutual enhancement of toxic effects. Tricyclic antidepressants, oral contraceptives, and allopurinol also increase its toxicity. Barbiturates and phenylbutazone weaken the effect of analgin.
Concomitant use of Tempanginol® with cyclosporine reduces the blood level of the latter.
Sedatives and anxiolytics enhance the analgesic effect of the drug.
When used concomitantly, Tempanginol® enhances the effects of oral hypoglycemic agents, indirect anticoagulants, glucocorticosteroids, and indomethacin.
Storage Conditions
In a dry, light-protected place, out of reach of children, at a temperature of 15-25°C (59-77°F).
Shelf Life
Shelf life – 4 years. Do not use after the expiration date printed on the packaging.
Dispensing Status
The drug is approved for use as an over-the-counter product.
Important Safety Information
This information is for educational purposes only and does not replace professional medical advice. Always consult your doctor before use. Dosage and side effects may vary. Use only as prescribed.
Medical Disclaimer